Pricing Log in Create free account
Sunday 18 October 2026 Export AVIR’s income statement to Excel — free account

Atea Pharmaceuticals, Inc.

AVIR Healthcare Biotechnology

In the quarter to June 2026, EPS grew 6.82% and free cash flow grew 85.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

4.32 0.21 −4.64%
Market cap
$363.3M
P/E
0.0×
Fwd P/E
−2.5×
Dividend yield
—
F-score
n/a
Altman Z
9.33
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Atea Pharmaceuticals, Inc. (AVIR) Business Profile

Updated before January 2025

Company Overview

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative antiviral therapeutics. Founded in 2012 and headquartered in Boston, Massachusetts, Atea focuses on addressing unmet medical needs in the treatment of viral infections. The company was established by a team of seasoned pharmaceutical executives and scientists with extensive experience in antiviral drug development. Jean-Pierre Sommadossi, Ph.D., serves as the Chairman and Chief Executive Officer, bringing decades of expertise in the biotechnology and pharmaceutical industries. Under his leadership, Atea has built a robust pipeline of antiviral candidates aimed at combating a range of viral diseases.

Core Business Segments

Antiviral Therapeutics

Atea Pharmaceuticals specializes in the development of oral direct-acting antiviral (DAA) therapies. The company’s primary focus is on creating treatments for viral infections that pose significant global health challenges. Key products and programs include:

  • Bemnifosbuvir (AT-527): A nucleotide prodrug designed to inhibit the replication of RNA viruses, including SARS-CoV-2, the virus responsible for COVID-19. Bemnifosbuvir is currently in clinical trials and has shown promise as a potential treatment for COVID-19.
  • Hepatitis C Virus (HCV) Program: Atea is leveraging its expertise in nucleotide prodrug chemistry to develop therapies for HCV, aiming to provide effective and convenient treatment options.
  • Other Viral Targets: The company is also exploring treatments for other RNA viruses, including respiratory syncytial virus (RSV) and dengue virus, as part of its broader antiviral pipeline.

Research and Development (R&D)

Atea invests heavily in R&D to advance its pipeline of antiviral candidates. The company employs a multidisciplinary approach, combining medicinal chemistry, virology, and pharmacology to design and optimize its drug candidates. This commitment to innovation positions Atea as a leader in the antiviral therapeutics space.

Business Model

Atea Pharmaceuticals operates on a research-driven business model, focusing on the discovery and development of novel antiviral therapies. The company generates revenue through strategic partnerships, licensing agreements, and potential future product sales. Key elements of its business model include:

  • Collaborations: Atea collaborates with leading pharmaceutical companies to accelerate the development and commercialization of its drug candidates. For example, the company previously partnered with Roche to advance the development of bemnifosbuvir.
  • Intellectual Property: Atea maintains a strong intellectual property portfolio to protect its proprietary technologies and drug candidates.
  • Clinical Development: The company conducts rigorous clinical trials to evaluate the safety and efficacy of its therapies, ensuring compliance with regulatory standards.

Strategic Direction

Atea Pharmaceuticals is committed to addressing the global burden of viral diseases through the development of innovative antiviral therapies. Key strategic priorities include:

  • Advancing Bemnifosbuvir: Atea aims to complete clinical trials for bemnifosbuvir and secure regulatory approval for its use in treating COVID-19 and other RNA virus infections.
  • Expanding the Pipeline: The company is actively exploring new therapeutic targets and indications to broaden its portfolio of antiviral candidates.
  • Sustainability Goals: Atea is dedicated to sustainable practices in its operations, including minimizing its environmental footprint and promoting ethical business practices.
  • Global Reach: The company seeks to expand its presence in international markets, ensuring access to its therapies for patients worldwide.

Competitive Landscape

Atea Pharmaceuticals operates in a highly competitive biopharmaceutical sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Gilead Sciences: A leader in antiviral therapies, particularly for HIV and HCV.
  • Pfizer: A major player in the COVID-19 treatment and vaccine space.
  • Merck & Co.: Known for its antiviral drug development programs.
  • Moderna and BioNTech: Companies specializing in mRNA-based therapies and vaccines.

Despite the competitive landscape, Atea differentiates itself through its focus on oral direct-acting antivirals and its expertise in nucleotide prodrug chemistry.

Risk Factors

Atea Pharmaceuticals faces several risks that could impact its business operations and financial performance, including:

  • Regulatory Risks: Delays or failures in obtaining regulatory approvals for its drug candidates could hinder commercialization efforts.
  • Market Dependence: The company’s reliance on a limited number of drug candidates increases its exposure to market risks.
  • Supply Chain Disruptions: Challenges in sourcing raw materials or manufacturing drug products could delay clinical trials and product launches.
  • Competition: Intense competition from larger pharmaceutical companies with greater resources could limit Atea’s market share.
  • Financial Risks: As a clinical-stage company, Atea relies on external funding and may face challenges in securing additional capital.

Recent Developments

  • Clinical Trials: Atea has made significant progress in advancing bemnifosbuvir through clinical trials, with promising data supporting its potential as a COVID-19 treatment.
  • Partnerships: The company continues to explore strategic collaborations to enhance its R&D capabilities and accelerate drug development.
  • COVID-19 Impact: The global pandemic has underscored the importance of antiviral therapies, positioning Atea as a key player in addressing this urgent medical need.

Investment Considerations

Strengths

  • Innovative Pipeline: Atea’s focus on oral direct-acting antivirals positions it as a leader in the antiviral therapeutics space.
  • Experienced Leadership: The company’s management team brings extensive expertise in drug development and commercialization.
  • Strategic Partnerships: Collaborations with leading pharmaceutical companies enhance Atea’s R&D capabilities and market reach.

Risks

  • Clinical and Regulatory Uncertainty: The success of Atea’s drug candidates depends on positive clinical trial outcomes and regulatory approvals.
  • Market Competition: Intense competition from established players could limit Atea’s growth potential.
  • Financial Dependence: As a clinical-stage company, Atea relies on external funding to support its operations.

Conclusion

Atea Pharmaceuticals, Inc. is a promising biopharmaceutical company with a strong focus on antiviral therapeutics. Its innovative pipeline, experienced leadership, and strategic partnerships position it as a key player in addressing global health challenges. While the company faces risks associated with clinical development and market competition, its commitment to innovation and strategic growth provides a solid foundation for future success. Investors should carefully consider both the opportunities and risks associated with Atea as it continues to advance its mission of improving global health through antiviral therapies.